<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01620333</url>
  </required_header>
  <id_info>
    <org_study_id>BIASP-1164</org_study_id>
    <nct_id>NCT01620333</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers</brief_title>
  <official_title>A Randomised, Open-labelled, Single-centre, Two-period Crossover Trial Characterizing the Pharmacokinetics and Pharmacodynamics of NN-X14Mix50 and NN-X14Mix70 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Japan. The aim of this trial is to investigate the
      pharmacokinetics of biphasic insulin aspart 50 (NN-X14Mix50) and biphasic insulin aspart 70
      (NN-X14Mix70) in Japanese healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">April 2000</completion_date>
  <primary_completion_date type="Actual">April 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the insulin aspart curve in the interval from 0 to 24 hours (BIAsp 70)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax, maximum insulin aspart concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax, time to maximum insulin aspart concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½, terminal elimination half life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time 0 to infinity (0-∞)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the insulin aspart curve in the interval from 0 to 24 hours (BIAsp 50)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 50</intervention_name>
    <description>A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days</description>
    <arm_group_label>Treatment period 1</arm_group_label>
    <arm_group_label>Treatment period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 70</intervention_name>
    <description>A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days</description>
    <arm_group_label>Treatment period 1</arm_group_label>
    <arm_group_label>Treatment period 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  Japanese

          -  Body Mass Index (BMI) of 19-27 kg/m^2 (both inclusive)

          -  Fasting blood glucose between 3.8-6 mmol/L (68.4-108.0 mg/dL) (both inclusive

          -  Considered generally healthy upon completion of medical history and physical
             examination, as judged by the Investigator or Sub-Investigator

        Exclusion Criteria:

          -  Clinically significant abnormal haematology or biochemistry screening tests, as judged
             by the Investigator or Sub-Investigator(s)

          -  Any serious systemic infectious disease that occurred during the 4 weeks prior to the
             screening, as judged by the Investigator or Sub-Investigator

          -  Any inter-current illness that may affect blood glucose, as judged by the Investigator
             or Sub-Investigator

          -  Hepatitis B or C, or HIV (human immunodeficiency virus)

          -  Use of prescription drugs within 2 weeks preceding the screening

          -  Use of non-prescription drugs, except routine vitamins or drugs that may not

          -  Blood donation of more than 1150 mL within the last 12 months

          -  Subjects with a first degree relative with diabetes mellitus

          -  History of or presence of diabetes

          -  History of or presence of cancer or any clinically significant cardiac, respiratory,
             metabolic, renal, hepatic, gastrointestinal, endocrinological, dermatological,
             venereal, haematologic, neurologic, or psychiatric diseases or disorder

          -  Previous history of serious allergy or anaphylactic reaction

          -  Subjects who consume more than 28 units of alcohol per week or who have a significant
             history of alcoholism or drug/chemical abuse

          -  Subjects who smoke more than 5 cigarettes per day
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR,1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>1000005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Irie S, Furuie H, Matsuguma K, Matsumura Y. Pharmacokinetics and pharmacodynamics of biphasic insulin aspart 50 and biphasic insulin aspart 70 in healthy Japanese subjects. Diabetologia 2006; 49 (Suppl 1): 612</citation>
  </results_reference>
  <results_reference>
    <citation>Irie S, Matsumura Y, Furuie H, Matsuguma K. Comparison of the pharmacokinetic and pharmacodynamic properties of biphasic insulin aspart 50 and biphasic insulin aspart 70 in healthy Japanese. Diabetic Medicine 2006; 23 (Suppl 4): 331 (P915)</citation>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>June 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <last_update_submitted>January 4, 2017</last_update_submitted>
  <last_update_submitted_qc>January 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

